Surmodics Reports Fourth Quarter Fiscal 2018 Results and Issues Fiscal 2019 Guidance


Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today We continue to drive strong revenue growth and solid operational performance as we execute on our strategic objectives, said Gary Maharaj, President & CEO of Surmodics. The positive twelve-month data recently presented from PREVEIL, the early feasibility study of our SurVeil® DCB and the recent submission for first in-human study for our AV access DCB, AVess, demonstrate meaningful progress towards Total revenue for the fourth quarter of fiscal 2018 was $23.0 million, as compared with $20.1 million in the prior-year period. Medical Device revenue was $17.0 million in the fourth quarter of fiscal 2018, as compared with $14.7 million in the year-ago period, an increase of 15.4%, and includes $2.2 million from our SurVeil agreement with Abbott. In Vitro Diagnostics revenue was $6.1 million for the fourth quarter Diluted GAAP loss per share in the fourth quarter of fiscal 2018 was $(0.13) as compared with diluted GAAP earnings per share of $0.03 in the year-ago period. On a non-GAAP basis, earnings per share were …[Read on via official release]

Source: US SEC
View full document: 8-K_for_SURMODICS_INC_8-K-11-09-2018